EX-10.110-Q·CIK 1788028·0001213900-26-120161

License Agreement, Dated June 9, 2017, by and Between the Trustees of the University of Pennsylvania and Kira Pharmaceuticals

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 08:06 EST

Exhibit 10.1

Execution Version

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.

LICENSE AGREEMENT

DATED AS OF JUNE 9, 2017

BY AND BETWEEN

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

AND

KIRA PHARMACEUTICALS

Table of Contents

Page
Article 1 DEFINITIONS 1
Article 2 LICENSES AND OTHER RIGHTS 7
Article 3 DILIGENCE 9
Article 4 FINANCIAL PROVISIONS 10
Article 5 INTELLECTUAL PROPERTY 14
Article 6 REPRESENTATIONS, WARRANTIES AND COVENANTS 18
Article 7 INDEMNIFICATION; INSURANCE AND LIMITATION OF LIABILITY 19
Article 8 TERM AND TERMINATION 21
Article 9 ADDITIONAL PROVISIONS 23

Exhibit A Penn Patent Rights

EXHIBIT B Certain FINANCIAL TERMS

Appendix I Form of Financial Report

Appendix II Client & Billing Agreement

APPENDIX III Development Plan

Appendix IV Sublicense Development Report

i

LICENSE AGREEMENT

This License Agreement (this “Agreement”) is dated as of June 9, 2017 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Kira Pharmaceuticals, a corporation registered and existing under the laws of the Cayman Islands (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.

RECITALS:

** **

WHEREAS, Penn owns and controls certain innovative technology for treating complement mediated diseases (Penn references [***], [***] and [***]) as further defined herein, that were developed in the course of research at Penn by Dr. Wenchao Song, and others (the “Inventor(s)”);

** **

WHEREAS, Penn filed certain provisional patent applications covering the technology;

** **

WHEREAS, Penn desires to license, to Licensee, Penn’s intellectual property rights in such technology, in a manner that will benefit the public and best facilitate the distribution of useful products and the utilization of new technology, consistent with Penn’s educational and research missions and goals; and

** **

WHEREAS, Licensee desires to license from Penn, Penn’s intellectual property rights in such technology, to develop, manufacture and commercialize such technology, all on the terms and conditions of this Agreement.

** **

NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows:

** **

Article 1

DEFINITIONS

Unless otherwise specifically provided herein, the following terms shall have the following meanings:

1.1 “Achievement Date” means, with respect to a Diligence Event, the corresponding date such Diligence Event is to be achieved as provided in Exhibit B attached hereto subject to modification pursuant to Section 3.3 below.
1.2 “Affiliate” means a Person that controls, is controlled by or is under common control with a Party, but only for so long as such control exists. For the purposes of this Section 1.2, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.
1.3 “Change of Control” means the occurrence of any of the following events (including through a transaction or series of transactions): (i) any party becomes the owner, directly or indirectly, of more than fifty percent (50%) of the total voting power (on an as converted basis) of the equity units or other interests of Licensee then outstanding that are normally entitled to vote in the election of directors of Licensee; (ii) the merger, consolidation or amalgamation of Licensee with or into any other party, other than any transaction in which the holders of the outstanding voting securities of Licensee immediately prior to the transaction own, directly or indirectly, not less than fifty percent (50%) of the total voting power (on an as converted basis) of the voting securities of the party surviving such merger, consolidation or amalgamation; (iii) the sale, transfer or other disposition of all or substantially all of the assets of Licensee (iv) the sale transfer or other disposition of this Agreement; (v) an initial public offering of the stock or securities of Licensee in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction resulting in at least [***] in gross proceeds to the Licensee and where the closing of the sale of shares Licensee to the public is at a price of at least [***] the price of the per share price sold in the first private securities financing of the Licensee in which an institutional investor participates in (“IPO”).
1
1.4 “Combination Product” means a Product together with one or more products, devices, pieces of equipment or components thereof that in each case is also sold independently, but sold for a single price.
1.5 “Commercially Reasonable Efforts” means the efforts and resources that [***]. Without limiting the foregoing, Commercially Reasonable Efforts requires, with respect to such obligations, that the Party (a) promptly assign responsibility for such obligation to specific employee(s) who are accountable for progress and monitor such progress on an on-going basis, (b) set annual objectives for carrying out such obligations, and (c) allocate resources designed to advance progress with respect to such objectives.
1.6 “Compulsory License” means a compulsory license under Penn Patent Rights obtained by a Third Party through the order, decree, or grant of a competent Governmental Body or court, authorizing such Third Party to develop, make, have made, use, sell, offer to sell or import a Product in any country in the Territory.
1.7 “Confidential Information” of a Party, means (i) information relating to the business, operations or products of a Party or any of its Affiliates, including any know-how, that such Party discloses to the other Party under this Agreement, or otherwise becomes known to the other Party by virtue of this Agreement, and (ii) the terms, but not the existence, of this Agreement; provided that Confidential Information shall not include information that:
(a) is or becomes generally available to the public other than as a result of disclosure by the recipient;
(b) is already known by or in the possession of the recipient at the time of disclosure by the disclosing Party;
(c) is independently developed by recipient without use of or reference to the disclosing Party’s Confidential Information; or
(d) is obtained by recipient from a Third Party that has not breached any obligations of confidentiality.
1.8 “Controlled” means, with respect to property rights (intellectual property or otherwise), that a Party or one of its Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide to, grant a license or sublicense to, or assign its right, title and interest in and to, such intellectual property rights as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party.
2
1.9 “Development Plan” means the development plan provided by Licensee to Penn that provides the activities, and the associated timelines of when such activities shall be conducted (including in detail the activities that shall be conducted in the calendar year following the submission of such Development Plan to Penn), in order to develop a Product covered by each Patent Family for commercialization. The initial Development Plan is attached hereto as Appendix III.
1.10 “Diligence Event” means each of the events that Licensee is expected to accomplish in the development of a Product as provided in Exhibit B attached hereto.
1.11 “Field of Use” means any and all uses.
1.12 “First Commercial Sale” means, on a country-by-country basis, the first commercial transfer or disposition for value of Product in such country to a Third Party by Licensee, or any of its Affiliates or Sublicensees, in each case, after all Governmental Approvals have been obtained for such country.
1.13 “GAAP” means United States generally accepted accounting principles applied on a consistent basis.
1.14 “Governmental Approval” means, with respect to a Product in a country or region, all approvals, licenses, registrations and authorizations of the relevant Governmental Body, if applicable, required for the commercialization of such Product in such country.
1.15 “Governmental Body” means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, provincial, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi-national or supranational organization or body; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.
1.16 **“Intellectual Property” **means the Penn Patent Rights.
1.17 “Law” or “Laws” means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect of law of any Governmental Body.
1.18 “Net Sales” means the gross consideration invoiced or received by Licensee or any of its Affiliates or Sublicensees for Sales of Product (including any cash amounts plus the fair market value of any other forms of consideration), less the following deductions (to the extent included in and not already deducted from the gross amounts invoiced or otherwise charged) to the extent reasonable and customary and solely related to the sale of the Product(s):
1.18.1 [***]
1.18.2 [***]
1.18.3 [***]
1.18.4 [***]
1.18.5 [***]
3
1.18.6 [***]
1.18.7 [***]

Even if there is overlap between any of deductions described above, each individual item shall only be deducted once in the overall Net Sales calculation. Each of the above deductions to Net Sales shall be calculated in accordance with US GAAP.

Notwithstanding the foregoing, Net Sales shall not include, and shall be deemed zero with respect to: (i) the distribution of promotional samples of Products provided free of charge, and, (ii) Products provided for clinical trials or research, development, or evaluation purposes, provided that such Products do not exceed [***] of Net Sales of such Product in any given year after the First Commercial Sale of such Product.

Net Sales of any Combination Product shall be determined on a country-by-country basis as follows: the Net Sales of the Combination Product (prior to application of the following adjustment) shall be multiplied by the fraction A/(A+B), where A is the net selling price in such country of a Product without the additional product/device/component in the Combination Product, and B is the net selling price in such country of such product/device/component in the combination if sold separately in the same metric or form as contained in the Combination Product. All net selling prices of the elements of such Combination Product shall be calculated as the average net selling price of the said elements during the applicable accounting period for which the Net Sales are being calculated.

1.19 “Patent Family” means the Penn Patent Rights listed in Exhibit A that are associated with discrete patent families, namely, the “fD Patent Family” which means Penn Patent Rights with the Penn reference [***]; the “C5 Patent Family” which means Penn Patent Rights with the Penn reference [***]; and the “C5a Patent Family” which means Penn Patent Rights with the Penn reference [***] (each of fD Patent Family, C5 Patent Family and C5a Patent Family, a “Patent Family” and collectively, the “Patent Families”).
1.20 “Patent Rights” means any of the following, whether existing now or in the future anywhere in the world: issued patent, including inventor’s certificates, substitutions, extensions, confirmations, reissues, re-examination, renewal or any like governmental grant for protection of inventions, and any pending application for any of the foregoing.
1.21 “Penn Mouse Models” means the mouse models listed in Exhibit C, Controlled by Penn as of the Effective Date.
1.22 “Penn Patent Rights” means (a) the Patent Rights listed in Exhibit A Controlled by Penn as of the Effective Date, (b) any continuations, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, reexaminations, renewals or reissues thereof, including divisions, but excluding continuations-in-part except to the extent of claims entirely supported in the specification and entitled to the priority date of the parent application, and (c) any corresponding foreign Patent Rights to the foregoing. Notwithstanding the above, Penn Patent Rights do not include the Carve-Out Patent Rights or any Patent Right for which this Agreement has been terminated, including under Sections 8.2 or 8.3.2.
1.23 “Person” means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof.
4
1.24 “Product” means any (a) process, service or method covered by a Valid Claim or whose use or practice would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Valid Claim (“Method”), (b) article, composition, apparatus, substance, chemical or any other material covered by a Valid Claim or whose manufacture, import, use offer for sale or sale would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Valid Claim; or (c) service, article, composition, apparatus, chemical, substance or any other material made, used or sold by or utilizing or practicing a Method.
1.25 “Royalty Term” means, with respect to each Product in each country, the term commencing on the date of the First Commercial Sale in such country and ending in such country upon the later of: (i) the expiration of the last Valid Claim of the Penn Patent Rights that covers the right to make, have made, use, sell, offer for sale and import such Product in such country and (ii) [***] following the date of First Commercial Sale of the first Product in such country.
1.26 “Sale” means any transaction for which consideration is received or expected by Licensee, its Affiliates or Sublicensees for sale, use, lease, transfer or other disposition of a Product to or for the benefit of a Third Party. For clarity, sale, use, lease, transfer or other disposition of a Product by Licensee or any of its Affiliates or Sublicensees to another of these entities for resale by such entity to a Third Party shall not be deemed a Sale.
1.27 “Sublicensee” means a Person (including any Affiliate) to which a Sublicense is granted pursuant to the terms of Section 2.4.
1.28 “Sublicense Documents” means any and all agreements, amendments or written understandings entered into with a Sublicensee (including any of its Affiliates) that are directly or indirectly related to a Sublicense, Penn Patent Rights or Product. For clarity, a development agreement or distribution agreement for a Product is a Sublicense Document.
1.29 “Sublicense Income” means income received by Licensee or its Affiliates in consideration for a Sublicense or other agreement providing the right to negotiate or obtain a Sublicense. Sublicense Income includes income received from a Sublicensee in the form of license issue fees, milestone payments and the like but specifically excludes: (a) royalties on the sale or distribution of Product; (b) fair market purchases of equity or debt of Company or any Affiliate, and (c) fair market value payments that are (i) made in connection with research and development services, where Company or an Affiliate is obligated to perform research and development of any Product(s) and (ii) directly related to a Product, which shall be calculated based upon direct costs associated with such services provided by Company or its Affiliates on behalf of Sublicensee with an allowance for overhead charge as separately reported to Penn with appropriate written documentation, which shall not be greater than [***] for commercial entities or the Facilities and Administrative (F&A) cost rate so established by the federal government for the applicable research institution(s).
1.30 “Tax” means all taxes, duties, fees, premiums, assessments, imposts, levies, rates, withholdings, dues, government contributions and other charges of any kind whatsoever, whether direct or indirect, together with all interest, penalties, fines, additions to tax or other additional amounts, imposed by any Governmental Body.
1.31 “Third Party” means any Person other than Penn, Licensee or any of their respective Affiliates.
1.32 “Transaction Value” means the fair market value of Licensee, taken as a whole, determined based upon all consideration, including but not limited to cash, securities, property, rights (contractual or otherwise), dividends or other form of consideration, paid or payable, or otherwise to be distributed, directly or indirectly to all parties in the Change of Control transaction.
5
1.33 “United States” or “US” means the United States of America, its territories and possessions.
1.34 “USD” or “$” means the lawful currency of the United States of America.
1.35 “Valid Claim” means a claim of (a) an issued and unexpired patent in Penn Patent Rights which claim has not been revoked or held unenforceable or invalid by a decision of a court of governmental agency of competent jurisdiction from which no further appeal can be taken or has been taken within the time allowed for appeal, and has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer; or (b) a pending patent application that is included in Penn Patent Rights which was filed and is being prosecuted in good faith, and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application.
1.36 Other Terms. The definition of each of the following terms is set forth in the section of this Agreement indicated below:
Defined Term ** ** Section
Advance Payment 5.2.2
Agreement Preamble
Bankruptcy Action 8.3.5
Carve-Out Patent Rights 5.1.2
Disclosure Recitals
Effective Date Preamble
Exclusive License 2.1
Financial Report 4.8
Historic Patent Cost 5.2.1
Infringement Notice 5.4.1
Inventor(s) Recitals
Issue Fee 4.1
License 2.1
Licensee Preamble
Maintenance Fee 4.3
Method 1.22
Milestone 4.4.1
Milestone Payment 4.4.1
Minimum Annual Royalty 4.5.5
Non-Exclusive License 2.1
Notice 3.2
Ongoing Patent Costs 5.2.2
Parties Preamble
Party Preamble
Patent Costs 5.2.1
Patent Counsel 5.1.1
Patent Termination Notice 5.3
Penn Preamble
Penn Indemnitees 7.1.1
Penn Sublicense Income 4.6
Plan 3.2
Product Bundle 1.17.6
Progress Reports 3.4.1
Prosecution Request 5.1.2
Royalty 4.5.1
SDR Report 2.4.4
Sublicense 2.4.1
Term 8.1
6

** **

Article 2

LICENSES AND OTHER RIGHTS

2.1 Grant of License. Subject to the terms and conditions of this Agreement, Penn hereby grants to Licensee (a) an exclusive, worldwide, royalty-bearing right and license (with the right to sublicense as provided in, and subject to, the provisions of Section 2.4) under Penn Patent Rights to make, have made, use, sell, offer for sale and import Product in the Field of Use during the Term (the “Exclusive License”), and (b) a non-exclusive, sublicensable (only to the extent that such sublicense is in connection with the sublicense of the Penn Patent Rights) license to use the Penn Mouse Models for internal research purposes only (the “Non-Exclusive License”). The Exclusive License and Non-Exclusive License will be collectively referred to as the “License”.
2.2 Retained Rights. Notwithstanding the License, Penn retains the right under Penn Patent Rights to: (a) conduct educational and research and clinical activities itself and (b) authorize non-commercial Third Parties to conduct educational and research and clinical activities. Penn also reserves the right to use, and to permit other entities to use, the Penn Mouse Models for any purpose.
2.3 U.S. Government Rights. The License is expressly subject to all applicable provisions of any license to the United States Government executed by Penn and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. §§200-212, applicable governmental implementing regulations, and the U.S. Government sponsored research agreement or other guidelines, including that products that result from intellectual property funded by the United States Federal Government that are sold in the United States be substantially manufactured in the United States. In the event that Licensee believes in good faith that substantial manufacture of such product is not commercially feasible in the United States and makes a request to Penn in writing to assist in obtaining a waiver of such requirement from the United States Government, then Penn shall, at the expense of Licensee, use reasonable efforts to assist in obtaining such waiver.
2.4 Grant of Sublicense by Licensee.
2.4.1 Penn grants to Licensee the right to grant sublicenses, in whole or in part, under the License (each, a “Sublicense”) subject to the terms and conditions of this Agreement and specifically this Section 2.4. The term Sublicense shall include any grant of rights under the License by a Sublicensee to any downstream third party, such downstream third party shall also be considered a Sublicensee for purposes of this Agreement.
2.4.2 All Sublicenses will be (a) issued in writing, (b) to the extent applicable, include all of the rights of Penn and require the performance of obligations due to Penn (and, if applicable, the U.S. Government under 35 U.S.C. §§200-212) contained in this Agreement and (c) shall include no less than the following terms and conditions:
(a) Reasonable record keeping, audit and reporting obligations sufficient to enable Licensee and Penn to reasonably verify the payments due to Licensee and Penn under such Sublicense and to reasonably monitor such Sublicensee’s progress in developing and/or commercializing Product, provided that such obligations shall be no less stringent that those provided in this Agreement for Licensee.
7
(b) Infringement and enforcement provisions that do not conflict with the restrictions and procedural requirements imposed on Licensee and do not provide greater rights to Sublicensee than as provided in Section 5.4.
(c) Confidentiality provisions with respect to Confidential Information of Penn consistent with the restrictions on Licensee in Section 5.6 of this Agreement.
(d) Covenants by Sublicensee that are equivalent to those made by Licensee in Section 6.3.
(e) A requirement of indemnification of Penn by Sublicensee that is equivalent to the indemnification of Penn by Licensee under Section 7.1 of this Agreement.
(f) A requirement of obtaining and maintaining insurance by Sublicensee that is equivalent to the insurance requirements of Licensee under Section 7.2 of this Agreement, including coverage under such insurance of Penn as provided in Section 7.2.
(g) Restriction on use of Penn’s names etc. consistent with Section 9.4 of this Agreement.
(h) A requirement of antidiscrimination by Sublicensee no less stringent than that provided in Section 9.5 of this Agreement.
(i) A requirement that Penn is a third party beneficiary of such Sublicense.

Any Sublicense that does not include all of the terms and conditions set forth in this Section 2.4.2 or which is not issued in accordance with the terms and conditions set forth in this Section 2.4, shall be considered null and void with no further notice from Penn.

2.4.3 Within [***] after of the execution of a Sublicense Document, Licensee shall provide a complete and accurate copy of such Sublicense Document to Penn, in the English Language. Penn’s receipt of a Sublicense Document, however, will constitute neither an approval nor disapproval of the Sublicense Document nor a waiver of any right of Penn or obligation of Licensee under this Agreement.
2.4.4 Licensee shall provide an annual Sublicense Development Report on or before [***] of each year during the Term (“SDR Report”) a form of which is attached hereto as Appendix IV.
2.5 No Implied License. Each Party acknowledges that the rights and licenses granted in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party. All rights with respect to any know-how, patent or other intellectual property right rights that are not specifically granted herein are reserved to the owner thereof.

** **


8

** **

Article 3

DILIGENCE

3.1 Development Plan. No later than [***] of each year during the Term, Licensee and its Sublicensees shall submit an updated Development Plan, which shall include amendments and revisions to any long term development activities and a timeline for detailed activities to be conducted in the following calendar year, provided that such updated Development Plan for a given Product covered by a Patent Family shall not be due after the First Commercial Sale of such Product, and no Development Plan shall be due after the First Commercial Sale of Products covered by all Patent Families.
3.2 General Diligence. Licensee and its Sublicensees shall use Commercially Reasonable Efforts to develop and commercialize a Product covered by each of the Patent Families.
3.3 Diligence Events.
3.3.1 Licensee and its Sublicensees shall achieve each Diligence Event by the corresponding Achievement Date for a Product covered by one of the Patent Families. Licensee and its Sublicensees shall achieve each Diligence Event for a Product covered by a second Patent Family within [***] of the corresponding Achievement Date for a first Product. Licensee and its Sublicensees shall achieve each Diligence Event for a Product covered by a third Patent Family within [***] of the Achievement Date of a first Product. Licensee and its Sublicensees may extend any Achievement Date for a Diligence Event by [***] (which shall adjust subsequent Achievement Dates), but not more than [***] per Diligence Event by making a payment of [***], per increment, to Penn prior to the expiration of such Achievement Date for such Diligence Event. After the exhaustion of the extension right as provided in the sentence above, in the event prior to the expiration of an Achievement Date, Licensee presents to Penn a reasonable explanation on why it will not be able to achieve such Diligence Event prior to the Achievement Date and that Licensee has, and currently is, using Commercially Reasonable Efforts toward the completion of such Diligence Event, Penn will not unreasonably withhold, condition or delay a request for extension(s) to achieve such Diligence Event, subject to a fee to be negotiated by the Parties that in no event shall exceed [***].
3.3.2 Penn’s sole and exclusive remedy with respect to Licensee’s or its Sublicensees’ failure to achieve a Diligence Event by the corresponding Achievement Date shall be its right to terminate this Agreement.
3.4 Progress Reports.
3.4.1 So long as Licensee continues to develop Products, Licensee on a [***] basis, but in no event later than [***] and [***] of each calendar year, shall submit to Penn a progress report (each, a “Progress Report”) covering Licensee’s (and any Affiliates’ and Sublicensees’) activities related to the development of all Products and the obtaining of Governmental Approvals necessary for commercialization of Products.
3.4.2 Each Progress Report must include all of the following for each [***] period:
(a) [***]
(b) [***]
(c) [***]
(d) [***]
9
(e) [***]
(f) [***]
(g) [***]
(h) [***]
(i) [***]
(j) [***]

** **

Article 4

FINANCIAL PROVISIONS

4.1 Issue Fee. In partial consideration of the License, Licensee will pay to Penn on the Effective Date a license issue fee of [***] (“Issue Fee”). The Issue Fee is non-refundable and non-creditable against any other amounts, including any royalties due by Licensee.
4.2 Change of Control Fee. In the event the Licensee undergoes a Change of Control, Licensee will pay to Penn a Change of Control Fee as set forth on Exhibit B attached hereto within [***] of the Change of Control event.
4.3 License Maintenance Fee. As further consideration for the License, Licensee will pay an annual maintenance fee (“Maintenance Fee”) as set forth on Exhibit B attached hereto beginning on the [***] of the Effective Date until the year in which a Minimum Annual Royalty is paid. For clarity, the Maintenance Fee is non-refundable, is not an advance against royalties due to Penn or any other amounts due to Penn.
4.4 Milestone Payments.
4.4.1 As additional consideration for the License, Licensee will pay Penn the milestone payments (each, a “Milestone Payment”) provided in Exhibit B attached hereto upon each Product to achieve the corresponding milestone (each, a “Milestone”), whether achieved by Licensee or an Affiliate or Sublicensee. Licensee shall promptly notify Penn in writing of the achievement of any such Milestone and Licensee shall pay Penn in full the corresponding Milestone Payment within [***] of such achievement. For clarity, each Milestone Payment is non-refundable, is not an advance against royalties due to Penn or any other amounts due to Penn.
4.4.2 Each time a Milestone is achieved, then any other Milestone Payments with respect to earlier clinical and regulatory approval Milestones that have not yet been paid will be due and payable together with the Milestone Payment for the Milestone that was actually achieved. In the event the Licensee has paid for a Milestone in advance of achievement, it shall not have to pay a Milestone Payment on the actual achievement of such Milestone.
4.4.3 For clarity, milestones are due and payable on Products and on products that, upon FDA approval, would become Products.
4.4.4 Licensee shall pay Penn the Milestone Payments for the first Product in full. Notwithstanding the above or any other provision of this Agreement or its Exhibits or Appendices, until such time as a first Product covered by one of the Patent Families has achieved regulatory approval in the United States or elsewhere, Licensee shall not pay the full amount due for any additional Product covered by the same Patent Family achieving any Milestone on which a Milestone Payment would be due, but will pay instead [***] of the Milestone Payment for each additional Product covered by the same Patent Family achieving such Milestone. After a first Product achieves regulatory approval in the United States or elsewhere, all amounts that would have been paid for achievement of Milestones that were reduced pursuant to this Section will be paid by Licensee to Penn within [***]. For clarity, commencing with the date upon which a first Product achieves regulatory approval in the United States or elsewhere, Licensee shall pay Penn the full amount of Milestone Payment on all Products achieving such Milestones at the time of achievement.
10
4.5 Royalties.
4.5.1 As further consideration for the License, Licensee shall pay during the Royalty Term to Penn a non-refundable, non-creditable royalty, on a Product-by-Product basis, on all Net Sales of such Product (“Royalty”) as set forth on Exhibit B attached hereto.
4.5.2 Notwithstanding anything in this Section 4.5, in the event that Penn or Licensee receives a request for a Compulsory License anywhere in the world, it shall promptly notify the other Party. If any Third Party obtains a Compulsory License in any country, then Penn or Licensee (whoever has first notice) shall promptly notify the other Party. Thereafter, as of the date the Third Party obtained such Compulsory License in such country, the royalty rate payable under this Section 4.5 to Penn for Net Sales in such country will be adjusted to equal any lower royalty rate granted to such Third Party for such country with respect to the Sales of such Product therein.
4.5.3 If Licensee is required, in the reasonable and good faith judgment of Licensee, to take a royalty bearing license to issued patents owned by a Third Party in order to make, use, sell, offer for sale or import Products, then Licensee may deduct [***] of the royalty paid to such Third Party from the Royalty due to Penn under this Agreement. In no event will the Royalty paid to Penn on Net Sales of such Products in any reporting period be so reduced to less than [***] of the amount that would otherwise be due to Penn under this Agreement. Licensee will provide a copy of any agreement pursuant to which it pays a Third Party amounts that are deducted from the Royalty due hereunder to Penn and such agreement may be redacted but only to the extent that the redacted content would not impair Penn’s calculation and interpretation of Licensee’s obligations related to royalty due to such Third Party; and within [***] of the end of a calendar year, Licensee will provide a report of the royalties paid to Third Parties used to deduct from the Royalties due to Penn. Notwithstanding the foregoing, if a disagreement between the Parties arises relating to such deduction for Third Party royalties, upon written request by Penn, Licensee shall provide to Penn a complete unredacted copy of the agreement in English.
4.5.4 Licensee must pay Royalties owed to Penn on a calendar quarter basis on or before the following dates:
(a) [***] for any Sales that took place on or before the last day of the calendar quarter ending December 31, of the prior year;
(b) [***] for any Sales that took place on or before the last day of the calendar quarter ending March 31 of such calendar year;
11
(c) [***] for any Sales that took place on or before the last day of the calendar quarter ending June 30 of such calendar year; and
(d) [***] for any Sales that took place on or before the last day of the calendar quarter ending September 30 of such calendar year.
4.5.5 Licensee shall pay to Penn the minimum annual royalties (“Minimum Annual Royalty”) provided in Exhibit B attached hereto during each of the following calendar years after the year in which the First Commercial Sale occurred in any country. Licensee will pay the Minimum Annual Royalty on [***] of each calendar year it is due, provided that the Minimum Annual Royalty paid for a calendar year shall be credited solely toward Royalties due in such calendar year.
4.6 Penn Sublicense Income. Licensee will pay to Penn a percentage of Sublicense Income as provided in Exhibit B attached hereto (“Penn Sublicense Income”). Licensee will make such payment to Penn on or before the following dates:
4.6.1 [***] for any Sublicense Income received by Licensee on or before the last day of the calendar quarter ending December 31, of the prior year;
4.6.2 [***] for any Sublicense Income received by Licensee on or before the last day of the calendar quarter ending March 31 of such calendar year;
4.6.3 [***] for any Sublicense Income received by Licensee on or before the last day of the calendar quarter ending June 30 of such calendar year; and
4.6.4 [***] for any Sublicense Income received by Licensee on or before the last day of the calendar quarter ending September 30 of such calendar year.
4.7 Mode of Payment and Currency. All payments to Penn hereunder shall be made by deposit of USD in the requisite amount to the “The Trustees of the University of Pennsylvania” and will be made by delivery to any one of the following:
By ACH/Wire: By Check (direct mail): By Check (lockbox):
[***] The Trustees of the The Trustees of the
[***] University of Pennsylvania University of Pennsylvania
[***] c/o Penn Center for Innovation c/o Penn Center for Innovation
[***] Attention: Financial PO Box 785546
[***] Coordinator Philadelphia, PA 19178-5546
Payment should include the necessary amount to cover any bank charges incurred. 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104-6283

Payments under this Agreement shall be made in USD. All Royalties payable shall be calculated first in the currency of the jurisdiction in which payment was made, and if not in the United States, then converted into USD. The exchange rate for such conversion shall be the average of the rate quoted in The Wall Street Journal for the last business day of each month in the calendar quarter for such Royalty payment made.

12
4.8 Royalty and Penn Sublicense Income Reports. Within [***] after the end of each calendar quarter (i.e. [***], [***], [***] and [***]), Licensee shall deliver to Penn a report (“Financial Report”) setting out all details necessary to calculate the Royalty and Penn Sublicense Income due under this Article 4 for such calendar quarter, including:
4.8.1 [***]
4.8.2 [***]
4.8.3 [***]
4.8.4 [***]
4.8.5 [***]
4.8.6 [***]
4.8.7 [***]
4.8.8 [***]

Each Financial Report shall be in the form of the sample report attached hereto as Appendix I.

4.9 Late Payments. In addition to any other remedies available to Penn, including the right to terminate this Agreement, any failure by Licensee to make a payment within [***] after the date when due shall obligate Licensee to pay computed interest, the interest period commencing on the due date and ending on the actual payment date, to Penn at a rate per annum equal to [***] per month, or the highest rate allowed by Law, whichever is lower.
4.10 Default Payment. In the event of default in payment of any payment owing to Penn under the terms of this Agreement, and if it becomes necessary for Penn to undertake legal action to collect said payment, Licensee shall pay reasonable, documented legal fees and costs incurred in connection therewith.
4.11 Accounting. Each Party shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable to it in accordance with GAAP.
4.12 Books and Records. Licensee will keep accurate books and records of all Products developed, manufactured, used or sold and all Sublicenses, collaboration agreements and joint venture agreements entered into by Licensee that involved Penn Patent Rights. Licensee will preserve these books and records for at least [***]from the date of the Financial Report to which they pertain. Upon reasonable notice, key personnel, books and records will be made reasonably available and will be open to examination by representatives or agents of Penn during regular office hours to determine their accuracy and assess Licensee’s compliance with the terms of this Agreement, provided that Licensee shall not have an obligation to provide access more than once in any given [***] period.
13
4.13 Audits. In addition to the right of Penn to examine the books and records and interview key personnel as provided in Section 4.12 above, Penn, at its own cost, through an independent auditor reasonably acceptable to Licensee (and who has executed an appropriate confidentiality agreement reasonably acceptable to Licensee that requires the auditor to keep any information learned by it confidential except as needed to report its audit conclusions to Penn), may inspect and audit the relevant records of Licensee pertaining to the calculation of any Milestones, Royalties and Penn Sublicense Income due to Penn under this Agreement. Licensee shall provide such auditors with access to the records during reasonable business hours. Such access need not be given to any such set of records more often than once each year or more than [***] after the date of any report to be audited. Penn shall provide Licensee with written notice of its election to inspect and audit the records related to the Milestones and Royalties due hereunder not less than [***] prior to the proposed date of review of Licensee’s records by Penn’s auditors. Should the auditor find any underpayment of Milestones, Royalties or Penn Sublicense Income by Licensee, Licensee shall (a) promptly pay Penn the amount of such underpayment; (b) shall reimburse Penn for the cost of the audit, if such underpayment equals or exceeds the higher of (i) [***] or (ii) [***] of Milestones, Royalties or Penn Sublicense Income paid during the time period audited; and (c) provide such auditors with an audit right exercisable within [***] after Penn receives the audit report. If the auditor finds overpayment by Licensee, then Licensee shall have the right to deduct the overpayment from any future milestones or royalties due to Penn by Licensee or, if no such future milestones or royalties are payable, then Penn shall refund the overpayment to Licensee within [***] after Penn receives the audit report. Licensee may designate competitively sensitive information which such auditor may see and review but which it may not disclose to Penn; provided, however, that such designation shall not restrict the auditor’s investigation or conclusions.
4.14 Taxes. All payments made by Licensee to Penn under this Agreement shall be made free and clear of and without any deduction for or on account of any Taxes on or with respect to such payments.

** **

Article 5

INTELLECTUAL PROPERTY

5.1 Patent Filing Prosecution and Maintenance.
5.1.1 Penn Patent Rights will be held in the name of Penn and obtained with counsel selected by Penn and reasonably acceptable to Licensee (“Patent Counsel”). Penn shall control all actions and decisions with respect to the filing, prosecution and maintenance of Penn Patent Rights and will consider any reasonable comments or suggestions by Licensee with respect to same. Penn will instruct Patent Counsel to copy Licensee on all correspondence related to Penn Patent Rights (including copies of each patent application, office action, response to office action, request for terminal disclaimer, and request for reissue or reexamination of any patent or patent application) and to interact with Licensee with respect to the preparation, filing, prosecution and maintenance of Penn Patent Rights. Penn has the right to take action to preserve rights and minimize cost whether or not Licensee has commented, and will use reasonable efforts to not allow any Penn Patent Rights for which Licensee is licensed and is underwriting the costs to lapse or become abandoned without Licensee’s written authorization under this Agreement, except for filing of continuations, divisionals, or the like that substitute for the lapsed application, provided that, Penn shall have no requirement to file, prosecute, or maintain Penn Patent Rights if Licensee is not current with the Patent Cost obligations as set forth in this Agreement. For the purposes of this Agreement, “maintenance” of the Penn Patent Rights includes inter partes patent review proceedings before the USPTO or a similar patent administration outside the US. For further clarity, validity challenges raised in infringement litigation will be handled per Section 5.4, Infringement.
14
5.1.2 Licensee has the right to request a country filing via a written request to Penn [***] prior to the deadline set by the patent office in the territory in which filing is to take place (“Prosecution Request”). The absence of a given Prosecution Request by such deadline will be considered an election not to secure the Patent Rights associated with the specific phase of patent prosecution in such territory, and such patent application(s) and patent(s) (“Carve-Out Patent Rights”) will not be part of Penn Patent Rights and therefore not subject to this Agreement, including the License, and Licensee will have no further rights or license to them.
5.1.3 If, and during such time that (i) Licensee is the only party to which Penn Patent Rights have been licensed to by Penn, (ii) there are no unpaid Historic Patent Costs or Ongoing Patent Costs, and (iii) Licensee requests to manage the filing, prosecution and maintenance of Penn Patent Rights, then Penn and Licensee will use reasonable efforts to enter into the Client and Billing Agreement with Patent Counsel in substantially the form attached hereto as Appendix II, which agreement upon execution shall, determine the management of Penn Patent Rights, in lieu of Section 5.1.1, provided that upon the termination of such agreement, the management of Penn Patent Rights shall be in accordance with Section 5.1.1.
5.2 Patent Costs.
5.2.1 Within [***] of the Effective Date, Licensee will reimburse Penn for all out-of-pocket costs for the filing, prosecution and maintenance of Penn Patent Rights, including all accrued attorney fees, expenses, official and filing fees (“Patent Costs”), incurred prior to the Effective Date (“Historic Patent Costs”).
5.2.2 Licensee will bear all Patent Costs incurred during the Term (“Ongoing Patent Costs”).
5.2.3 At any time, at Penn’s request, Licensee shall pay in advance the Patent Counsel’s estimated costs for undertaking material patent actions before Penn authorizes the Patent Counsel to proceed (“Advance Payment”). Notwithstanding whether Licensee makes an Advance Payment for any patent action, Licensee shall bear all Patent Costs incurred during the Term and shall pay such amounts within [***] of receipt of invoice for such patent actions. For clarity, the term “Patent Costs” means and includes Historic Patent Costs and Ongoing Patent Costs. For clarity, this Section 5.2.3 shall not apply during any period during the Term where a Client and Billing Agreement is in effect.
5.3 Termination of Rights in, and Obligations with respect to, Certain Penn Patent Rights. Licensee may terminate its rights in, and obligations with respect to any or all of Penn Patent Rights by providing written notice to Penn (“Patent Termination Notice”). Termination of Licensee’s rights in and obligation with respect to such Patent Right will be effective [***] after receipt of such Patent Termination Notice by Penn. Penn will use reasonable efforts to curtail Patent Costs chargeable to Licensee under this Agreement after the receipt of the Patent Termination Notice is received. Penn may continue prosecution and maintenance of such Patent Rights at its sole discretion and expense, and such Patent Rights will then be Carve-Out Patent Rights and therefore not subject to this Agreement, including the License, and Licensee will have no further rights or license to them.
5.4 Infringement.
5.4.1 If either Party believes that an infringement by a Third Party with respect to any Penn Patent Right is occurring or may potentially occur, the knowledgeable Party will provide the other Party with (a) written notice of such infringement or potential infringement and (b) evidence of such infringement or potential infringement (the “Infringement Notice”). During the period in which, and in the jurisdiction where, Licensee has exclusive rights under this Agreement, neither Penn nor Licensee will notify such Third Party (including the infringer) of infringement or put such Third Party on notice of the existence of Penn Patent Rights without first obtaining the written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. If Licensee puts such infringer on notice of the existence of any Penn Patent Rights without the prior written consent of Penn before Licensee provides the Required Evidence (as defined in Section 5.4.2), then License’s right to initiate a suit under Section 5.4.2 below will terminate immediately without the obligation of Penn to provide notice to Licensee. Both Penn and Licensee will use their diligent efforts to cooperate with each other to terminate such infringement without litigation.
15
5.4.2 If infringing activity of potential commercial significance has not been abated within [***] following the date the Infringement Notice for such activity was provided, then during the period in which, and in the jurisdiction where, Licensee has exclusive rights under this Agreement, Licensee may institute suit for patent infringement against infringer after providing Penn (a) a written estimate of the expenses that would be reasonably incurred in connection with such action, including an estimate from an outside law firm regarding the legal costs associated with such suit and (b) financial records reasonably sufficient to reasonably demonstrate that Licensee has the financial wherewithal to pay such expenses as they fall due through the conclusion of such suit by means of judgment or other final non-appealable decision (collectively subpart (a) and (b), the “Required Evidence”). Penn may voluntarily join such suit at Licensee’s reasonable expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Licensee’s suit or any judgment rendered in such suit. Licensee may not join Penn in a suit initiated by Licensee without Penn’s prior written consent, such consent not to be unreasonably withheld. If in a suit initiated by Licensee, Penn is involuntarily joined other than by Licensee, then Licensee will pay any costs incurred by Penn arising out of such suit, including any documented legal fees of counsel that Penn selects and retains to represent it in the suit. Licensee shall be free to enter into a settlement, consent judgment, or other voluntary disposition, provided that any settlement, consent judgment, or other voluntary disposition that (i) limits the scope, validity or enforcement of Penn Patent Rights or (ii) admits fault or wrongdoing on the part of Licensee or Penn must be approved in advance by Penn in writing. Licensee’s request for such approval shall include complete copies of final settlement documents, a detailed summary of such settlement, and any other information material to such settlement. Penn shall provide Licensee notice of its approval or denial within [***] of any request for such approval by Licensee, provided that (x) in the event Penn wishes to deny such approval, such notice shall include a detailed written description of Penn’s reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition and (y) Penn shall be deemed to have approved of such proposed settlement, consent judgment, or other voluntary disposition in the event it fails to provide such notice within such [***] period in accordance herewith.
5.4.3 If, within [***] following the date the Infringement Notice was provided, infringing activity of potential commercial significance has not been abated and if Licensee has not brought suit against the infringer, then Penn may institute suit for patent infringement against the infringer. If Penn institutes such suit, then Licensee may not join such suit without the prior written consent of Penn and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of Penn’s suit or any judgment rendered in such suit.
5.4.4 Notwithstanding Sections 5.4.2 and 5.4.3, in the event that any Penn Patent Rights are infringed by a Third Party and if any of the infringed Penn Patent Rights are also licensed by Penn to a Third Party for commercial use prior to any enforcement action being taken by either Party regarding such infringement, the Parties shall discuss, and will mutually agree, in writing, as to how to handle such infringement by such Third Party. Any recovery or settlement received in connection with any suit will first be shared by Penn and Licensee equally to cover any litigation costs each incurred and next shall be paid to Penn or Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other. Any remaining recoveries shall be allocated as follows:

For any portion of the recovery or settlement, other than for amounts attributable and paid as enhanced damages for willful infringement:

(a) for any suit that is initiated by Licensee and in which Penn was not a party in the litigation, Penn shall receive [***] of the recovery and the Licensee shall receive the remainder; and
16
(b) for any suit that is initiated by the Licensee or Penn and that the other Party joins voluntarily (but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily, the non-initiating party’s percentage of the total litigation costs incurred by Penn and Licensee, but in no event shall the non-initiating Party receive less than ten percent (10%) of such recovery, while the initiating party shall receive the remainder, and in no case shall Penn receive less than [***] of such recovery.

For any portion of the recovery or settlement paid as enhanced damages for willful infringement:

(c) for any suit that is initiated by Licensee or Penn and the other Party voluntarily (but only to the extent such voluntary joining is allowed under this Agreement or expressly by the other Party in a separate agreement) or involuntarily, the non-initiating party shall receive [***] and the initiating party shall receive the remainder; and
(d) for any suit that is initiated by Licensee and in which Penn was not a party in the litigation, Penn shall receive [***] and Licensee shall receive the remainder.

For any portion of the recovery or settlement received in connection with any suit that is initiated by Penn and in which Licensee was not a party in the litigation, any recovery in excess of litigation costs will belong to Penn.

5.4.5 Each Party will reasonably cooperate and assist with the other in litigation proceedings instituted hereunder but at the expense of the Party who initiated the suit (unless such suit is being jointly prosecuted by the Parties). For clarity, such requirement does not require a Party to join a suit unless otherwise specifically required under this Agreement. If Penn is subjected to third party discovery related to the Penn Patent Rights or Products licensed to Licensee hereunder, Licensee will pay Penn’s documented out of pocket expenses with respect to same.
5.5 Patent Marking. Licensee shall place in a conspicuous location on any Product (or its packaging where appropriate and practicable) made or sold under this Agreement a patent notice in accordance with the Laws concerning the marking of patented articles where such Product is made or sold, as applicable.
17
5.6 Confidentiality.
5.6.1 Each Party agrees that, for the Term and for [***] thereafter, such Party shall (a) use the same degree of care to maintain the secrecy of the Confidential Information of the other Party that it uses to maintain the secrecy of its Confidential Information of like kind, (b) use the Confidential Information only to accomplish the purpose of this Agreement or for audit or management purposes and (c) ensure that any employees, customers, and distributors are bound to it by similar obligations of confidence and to make sure such disclosure only as required to accomplish the purposes of this Agreement.
5.6.2 A Party may disclose the Confidential Information of the other Party to the extent required by Law or court order; provided, however, that, the recipient promptly provides to the disclosing Party (if permitted by applicable law, regulation or court order) prior written notice of such disclosure and provides reasonable assistance in obtaining an order or other remedy protecting the Confidential Information from public disclosure.

** **

Article 6

REPRESENTATIONS, WARRANTIES AND COVENANTS

6.1 Mutual Representations and Warranties. Each Party represents and warrants to the other Party that, as of the Effective Date:
6.1.1 such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation or organization;
6.1.2 such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement;
6.1.3 this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles; and
6.1.4 such Party has all right, power and authority to enter into this Agreement, to perform its obligations under this Agreement.
6.2 Representation of Licensee. Licensee represents and warrants that it shall have closed a financing prior to or as of the Effective Date pursuant to which it shall have raised not less than [***] for the operations of Licensee.
6.3 Disclaimer of Representations and Warranties.
6.3.1 Other than the representations and warranties provided in Sections 6.1 , PENN MAKES NO REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND EXPLICITLY DISCLAIMS ANY REPRESENTATION AND WARRANTY, INCLUDING WITH RESPECT TO ANY ACCURACY, COMPLETENESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE FOR THE INTELLECTUAL PROPERTY, PATENT RIGHTS, LICENSE AND ANY PRODUCT.
18
6.3.2 Furthermore, nothing in this Agreement will be construed as:
(a) A representation or warranty by Penn as to the validity or scope of any Penn Patent Right;
(b) A representation or warranty that anything made, used, sold or otherwise disposed of under the License is or will be free from infringement of patents, copyrights, trademarks or any other forms of intellectual property rights or tangible property rights of Third Parties;
(c) Obligating Penn to bring or prosecute actions or suits against Third Parties for patent, copyright or trademark infringement;
(d) Conferring by implication, estoppel or otherwise any license or rights under any Patent Rights of Penn other than Penn Patent Rights as defined herein, regardless of whether such Patent Rights are dominant or subordinate to Penn Patent Rights; and
(e) Obligating Penn to furnish any know-how.
6.4 Covenants of Licensee.
6.4.1 Licensee and its Affiliates will not, directly or indirectly (including where such is done by a Third Party on behalf of Licensee or its Affiliates, at the urging of Licensee or its Affiliates or with the assistance of the Licensee or its Affiliates) challenge the validity, scope, or enforceability of or otherwise oppose any Penn Patent Right, provided that if any Penn Patent Right is asserted against Licensee or its Affiliate for activities authorized under this Agreement, then such Licensee or its Affiliates is entitled to all and any defenses available to it including challenging the validity or enforceability of such Patent Right. Licensee will comply with all Laws that apply to its activities or obligations under this Agreement. For example, Licensee will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States government and/or written assurances by Licensee that Licensee will not export data or commodities to certain foreign countries without prior approval of the agency.
6.4.2 Licensee will not grant a security interest in the License or this Agreement without Penn’s prior written consent.
6.4.3 At no time during the Term, shall Dr. Wenchao Song or his family members (individually or in the aggregate) own or control a majority of the capital securities of Licensee, provided that this provision will remain in effect for so long as Dr. Wenchao Song is subject to the requirements of the Penn Patent Policy or applicable equivalent.

Article 7

INDEMNIFICATION; INSURANCE AND LIMITATION OF LIABILITY

7.1 Indemnification by Licensee.
7.1.1 Licensee shall defend, indemnify and hold Penn and its respective trustees, officers, faculty, students, employees, contractors and agents (the “Penn Indemnitees”) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees), including, without limitation, bodily injury, risk of bodily injury, death and property damage to the extent arising out of Third Party claims or suits related to (a) this Agreement or any Sublicense, including (i) the development, testing, use, manufacture, promotion, sale or other disposition of any Product (including any product liability claim), (ii) any enforcement action or suit brought by Licensee against a Third Party for infringement of Penn Patent Rights, (iii) any claim by a Third Party that the practice of Penn Patent Rights or the design, composition, manufacture, use, sale or other disposition of any Product infringes or violates any patent, copyright, trade secret, trademark or other intellectual property right of such Third Party, (iv) any breach of this Agreement or Laws by Licensee, its Affiliates or Sublicensees and (b) Licensee’s gross negligence, omissions or willful misconduct, provided that Licensee’s obligations pursuant to this Section 7.1 shall not apply to the extent such claims or suits result from the gross negligence or willful misconduct of any of Penn Indemnitees, as determined by a court of law.
19
7.1.2 As a condition to a Penn Indemnitee’s right to receive indemnification under this Section 7.1, Penn shall: (a) promptly notify Licensee as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) reasonably cooperate, and cause the individual Penn Indemnitees to reasonably cooperate, with Licensee in the defense, settlement or compromise of such claim or suit; and (c) permit the Licensee to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel. In no event, however, may Licensee compromise or settle any claim or suit in a manner which (a) admits fault or negligence on the part of Penn or any other Penn Indemnitee; (b) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action, without the prior written consent of Penn, or (c) grant any rights under the Penn Patent Rights except for Sublicenses permitted under Article 2. Penn shall reasonably cooperate with Licensee and its counsel in the course of the defense of any such suit, claim or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information and witnesses.
7.1.3 Notwithstanding Section 7.1.2 above, in the event that Penn believes in good faith that a bonafide conflict exists between Licensee and Penn or any other Penn Indemnitee with respect to a claim or suit subject to indemnification hereunder, then Penn or any other Penn Indemnitee shall have the right to defend against any such claim or suit itself, including by selecting its own counsel, with any reasonable attorney’s fees and litigation expenses being paid for by Licensee. Licensee will pay such fees and expenses either directly or will reimburse Penn within [***] of Licensee’s receipt of invoices for such fees and expenses.
7.2 Insurance.
7.2.1 Licensee, at its sole cost and expense, must insure its activities in connection with the exercise of its rights under this Agreement and obtain, and keep in force and maintain Commercial Form General Liability Insurance (contractual liability included) with limits as follows:
(a) Each occurrence [***];
(b) General aggregate [***]

*** ***

Prior to the commencement of clinical trials, if applicable, involving Product:

(c) Clinical trials liability insurance [***]

*** ***

Prior to the First Commercial Sale of a Product:

(d) Products liability insurance [***]

Penn and Licensee may periodically review the adequacy of the minimum amounts of insurance required by this Section 7.2.1, and shall mutually agree to adjust the limits should such a change be deemed prudent by the Parties.

7.2.2 If the above insurance is written on a claims-made form, it shall continue for [***] following termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement.
7.2.3 Licensee expressly understands, however, that the coverages and limits in Section 7.2.1 do not in any way limit Licensee’s liability or indemnification obligations. Licensee’s insurance will:
(a) Be issued by an insurance carrier with an A.M. Best rating of “A” or better;
(b) Provide for [***] advance written notice to Penn of any modification;
(c) State that Penn is endorsed as an additional insured with respect to the coverages in Section 7.2.1; and
(d) Include a provision that the coverages will be primary and will not participate with nor will be excess over any valid and collective insurance or program of self-insurance carried or maintained by Penn.
20

** **

7.2.4 Licensee must furnish to Penn with (a) valid certificate of insurance evidencing compliance with all requirements of this Agreement and (b) additional insured endorsements for Licensee’s applicable policies naming “The Trustees of the University of Pennsylvania” as an additional insured. Licensee must furnish both documents within [***] of the Effective Date, once per year thereafter and at any time there is a modification in such insurance.
7.3 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL LIMIT LICENSEE’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 7.1 ABOVE.

Article 8

TERM AND TERMINATION

8.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless terminated sooner as provided below, shall continue in full force and effect on a Patent Family-by-Patent Family basis until the expiration or abandonment of the last Valid Claim of a Penn Patent Right covering such Patent Family.
8.2 Termination for Convenience. At any time during the Term, Licensee may, at its convenience, terminate this Agreement in whole or on a Patent Family-by-Patent Family basis upon providing at least sixty (60) days prior written notice to Penn of such intention to terminate, provided that Licensee ceases using the License or making, using, or selling Products covered by such Patent Family or Patent Families.
8.3 Termination For Cause.
8.3.1 If Licensee fails to fulfill its obligations under Section 3.2 (i.e. use Commercially Reasonable Efforts to develop and commercialize a Product), Penn may provide written notice to Licensee of such failure. If Licensee fails to address such failure to the reasonable satisfaction of Penn within [***] of receiving such written notice, Penn may terminate this Agreement upon written notice to Licensee.
8.3.2 In the event that Licensee fails to achieve any Diligence Event for a second Patent Family or third Patent Family by its respective Achievement Date and no extension is granted by Penn, Penn may terminate the License for either the second or third Patent Family upon written notice to Licensee. Within [***] of such written notice from Penn, Licensee shall provide Penn of Licensee’s selection of which Patent Family to terminate (either the second or third) under this Section 8.3.2 and upon Licensee’s election, the License for such selected Patent Family shall be terminated. For clarity, the selection of which Patent Family shall be the terminated Patent Family under this Section 8.3.2 shall be at Licensee’s discretion.
8.3.3 If Licensee materially breaches any of its material obligations under this Agreement, Penn may give to Licensee a written notice specifying the nature of the default, requiring it to cure such breach, and stating its intention to terminate this Agreement. If such breach is not cured within [***] of such notice, such termination shall become effective upon a notice of termination by Penn thereafter. For clarity, a breach of a material obligation includes:
(a) failure to deliver to Penn any payment at the time or times that such payment is due to Penn under this Agreement;
(b) failure to provide reports as set forth in Sections 3.4.1 and 4.8;
(c) failure to possess and maintain insurance as set forth in Section 7.2;
(d) grant of a sublicense under the Penn Patent Rights that is not in accordance with the terms of this Agreement;
(e) failure to terminate a Sublicense where Sublicensee is in material breach of the obligations on it pursuant to (i) Sections 2.4.2(a), 2.4.2(c), 2.4.2 (e), 2.4.2(f) and 2.4.2(g) and fails to cure such breach within [***] of being notified of such breach and (ii) Section 2.4.2(d).
21
8.3.4 In addition to all other remedies available to it, Penn may terminate this Agreement, upon written notice, with immediate effect, upon a breach of Sections 6.2, 6.3.1 or 6.3.2.
8.3.5 Penn may terminate this Agreement, upon written notice, with immediate effect if, at any time, Licensee is unable to pay its debts, including any debts related to exclusive Sublicensees, when they come due, or files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of Licensee or of its assets, or if Licensee proposes a written agreement of composition or extension of its debts, or if Licensee is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within [***] after the filing thereof, or if Licensee proposes or is a party to any dissolution or liquidation, or if Licensee makes an assignment for the benefit of its creditors of all or substantially all its assets (in each case, “Bankruptcy Action”).
8.4 Effects of Termination.
8.4.1 Notwithstanding the termination of this Agreement, the following provisions shall survive: Sections 4.8-4.13, inclusive, 5.6 and 8.4 and 8.5 and Articles 6, 7 and 9.
8.4.2 Termination of this Agreement shall not relieve the Parties of any obligation or liability that, at the time of termination, has already accrued hereunder, or which is attributable to a period prior to the effective date of such termination. Termination of this Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation.
8.4.3 If this Agreement is terminated for any reason, all outstanding Sublicenses (including all Sublicense Documents for each Sublicense) not in default will be assigned by Licensee to Penn, and such assignment will be accepted by Penn. Each assigned Sublicense will remain in full force and effect with Penn as the licensor or sublicensor instead of Licensee, but the duties and obligations of Penn under the assigned Sublicenses will not be greater than the duties of Penn under this Agreement, and the rights of Penn under the assigned Sublicenses will not be less than the rights of Penn under this Agreement, including all financial consideration and other rights of Penn. Penn may, at its sole discretion, amend such outstanding Sublicenses to contain the terms and conditions found in this Agreement.
8.5 Inventory & Sell Off. Upon the termination of this Agreement for any reason, Licensee will cause physical inventories to be taken immediately of: (a) all completed Products on hand under the control of Licensee or its Affiliates or Sublicensees; and (b) such Products as are in the process of manufacture and any component parts on the date of termination of this Agreement. Licensee will deliver promptly to Penn a copy of the written inventory, certified by an officer of Licensee. Upon termination of this Agreement for any reason, Licensee will promptly remove, efface or destroy all references to Penn from any advertising, labels, web sites or other materials used in the promotion of the business of Licensee or its Affiliates, and Licensee and its Affiliates will not represent in any manner that it has rights in or to the Penn Patent Rights or the Products.Upon the termination of this Agreement for any reason other than pursuant to Section 8.2, 8.3.3(a), 8.3.3(c), 8.3.3(d), 8.3.3(e), 8.3.4, and 8.3.5, Licensee may sell off its inventory of Products existing on the date of termination for a period of [***] and pay Penn royalties on Sales of such inventory within [***] following the expiration of such [***] period.
22

** **

Article 9

ADDITIONAL PROVISIONS

9.1 Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. The Parties are independent contractors and at no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party.
9.2 Expenses. Except as otherwise provided in this Agreement, each Party shall pay its own expenses and costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby
9.3 Third Party Beneficiary. The Parties agree that each Sublicensee is a third party beneficiary of this Agreement with respect to Section 8.4.3.
9.4 Use of Names. Licensee, its Affiliates and Sublicensees may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative, without the prior written consent of Penn. Notwithstanding the foregoing, Licensee may use the name of Penn in a non-misleading and factual manner solely in (a) executive summaries, business plans, offering memoranda and other similar documents used by Licensee for the purpose of raising financing for the operations of Licensee as related to Product, or entering into commercial contracts with Third Parties, but in such case only to the extent necessary to inform a reader that the Penn Patent Rights has been licensed by Licensee from Penn, and to inform a reader of the identity and published credentials of Inventors of the Intellectual Property, and (b) any securities reports required to be filed with the Securities and Exchange Commission.
9.5 No Discrimination. Neither Penn nor Licensee will discriminate against any employee or applicant for employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status.
9.6 Successors and Assignment.
9.6.1 The terms and provisions hereof shall inure to the benefit of, and be binding upon, the Parties and their respective successors and permitted assigns.
9.6.2 Neither Party may assign or transfer this Agreement or any of its rights or obligations created hereunder, by operation of law or otherwise, without the prior written consent of the other Party, provided that the other Party shall not unreasonably withhold, condition or delay its consent. Notwithstanding the foregoing, Licensee may assign this Agreement, in part with respect to individual Patent Families, or in its entirety to a Third Party that is an entity that (together with its affiliates) had [***] or more in worldwide drug product revenues in the calendar year most recently completed as of the date of such assignment in connection with a sale or transfer of all or substantially all of Licensee’s business or assets for a Product without the prior written consent of Penn, provided that: (a) the assignee agrees in writing to be legally bound by this Agreement and delivers to Penn an updated Development Plan within [***] after the closing of the proposed transaction; (b) Licensee provides Penn with a copy of assignee’s undertaking; and (c) Licensee is not in breach under the terms and conditions of, and has paid all amounts owed to Penn under, this Agreement as of the date of such assignment. Any permitted assignment will not relieve Licensee of responsibility for performance of any obligation of Licensee that has accrued at the time of the assignment.
23
9.6.3 Any assignment not in accordance with this Section 9.6 shall be void.
9.7 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
9.8 Entire Agreement of the Parties; Amendments. This Agreement, the Exhibits and Appendices or Schedules hereto, Equity Issuance Agreement and, to the extent entered into, the Client & Billing Agreement constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.
9.9 Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.
9.10 Dispute Resolution. If a dispute arises between the Parties concerning this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the Parties are unable to resolve such dispute amicably, then the Parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania.
9.11 Notices and Deliveries. Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and directed to a Party at its address or facsimile number shown below or such other address or facsimile number as such Party shall have last given by notice to the other Party. A notice will be deemed received: if delivered personally, on the date of delivery; if mailed, [***] after deposit in the United States mail; if sent via courier, [***] after deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such notice is sent by certified mail, postage prepaid, return receipt requested.
For Penn
with a copy to:
Penn Center for Innovation University of Pennsylvania 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104-6283 Attention: Managing Director University of Pennsylvania Office of General Counsel 2929 Walnut Street, Suite 400 Philadelphia, PA 19104-5509 Attention: General Counsel
24
**_*For Licensee:*_** **_*with a copy to:*_**
Kira Pharmaceuticals c/o DLA Piper LLP (USA) DLA Piper LLP (USA) 1650 Market Street
1650 Market Street Suite 4900 Philadelphia, PA 19103 Attention: Fahd M.T. Riaz Suite 4900 Philadelphia, PA 19103 Attention: Fahd M.T. Riaz
9.12 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.
9.13 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under law, but if any provision of this Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.
9.14 Interpretation. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” All references herein to Articles, Sections, Schedules and Exhibits shall be deemed references to Articles and Sections of, Schedules and Exhibits to, this Agreement unless the context shall otherwise require. Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect from time to time. Unless the context otherwise requires, countries shall include territories. References to any specific Law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement Law thereto.
9.15 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.

** **

[SIGNATURE PAGE FOLLOWS]

25

IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Agreement as of the Effective Date.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA KIRA PHARMACEUTICALS
By: /s/ Benjamin Dibling, Ph.D. By:
Name: Benjamin Dibling, Ph.D. Name:
Title: Executive Director of Licensing, Penn Center for Innovation Title:

** **

[Signature Page to License Agreement]

** **

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA KIRA PHARMACEUTICALS
By: By: /s/ Gonghua Pan **
Name: John S. Swartley, PhD Name: Gonghua Pan
Title: Associate Vice Provost for Research and Managing Director, Title:
Penn Center for Innovation Date: July 25, 2017

[Signature Page to License Agreement]

** **

Exhibit A

Penn Patent Rights

[***]

** **

Exhibit B

Certain Financial Terms

[***]

** **

Exhibit C

Penn Mouse Models

[***]

** **

Appendix I

Form of Financial Report

[***]

Appendix II

Client & Billing Agreement

[***]

Appendix III

Development Plan

** **

[***]

** **

Appendix IV

Sublicense Development Report

** **

[***]

** **

Back to all agreements